Search research articles
Contact Us
Filters
Showing results (1-10 of 65) with videos related to
Page
of 7
Sort By:
Current Medical Research and Opinion
|
November 7, 2002
Clinical implications of dopamine research in schizophrenia
L Pani
Molecular Psychiatry
|
October 14, 2000
Is there an evolutionary mismatch between the normal physiology of the human dopaminergic system and current environmental conditions in industrialized countries?
L Pani
European Review for Medical and Pharmacological Sciences
|
January 21, 2010
The need for individualised antipsychotic drug therapy in patients with schizophrenia
L Pani
European Psychiatry : the Journal of the Association of European Psychiatrists
|
April 12, 2013
The role of limbic and cortical regions in schizophrenia: focus on dopamine
G Marchese, L Pani
Molecular Psychiatry
|
March 29, 2002
The substituted benzamides and their clinical potential on dysthymia and on the negative symptoms of schizophrenia
L Pani, G L Gessa
International Journal of Clinical Pharmacology Research
|
January 1, 1997
Evolution of the dopaminergic system and its relationships with the psychopathology of pleasure
L Pani, G L Gessa
Molecular Psychiatry
|
February 16, 2000
The role of stress in the pathophysiology of the dopaminergic system
L Pani, A Porcella, G L Gessa
The European Journal of Neuroscience
|
September 29, 1998
Delta9-tetrahydrocannabinol increases sequence-specific AP-1 DNA-binding activity and Fos-related antigens in the rat brain
A Porcella, G L Gessa, L Pani
Brain Research. Molecular Brain Research
|
January 1, 1996
Correlation between increased AP-1NGF binding activity and induction of nerve growth factor transcription by multiple signal transduction pathways in C6-2B glioma cells
A M Colangelo, L Pani, I Mocchetti
Psychopharmacology
|
January 1, 1989
Differential postmortem release of noradrenaline and dopamine from rat brain
Z L Rossetti, L Pani, G L Gessa
Page
of 7
Search research articles
Search
Showing results (1-10 of 65) with videos related to
Sort By:
Page
of 7
Current Medical Research and Opinion
|
November 7, 2002
Clinical implications of dopamine research in schizophrenia
L Pani
Molecular Psychiatry
|
October 14, 2000
Is there an evolutionary mismatch between the normal physiology of the human dopaminergic system and current environmental conditions in industrialized countries?
L Pani
European Review for Medical and Pharmacological Sciences
|
January 21, 2010
The need for individualised antipsychotic drug therapy in patients with schizophrenia
L Pani
European Psychiatry : the Journal of the Association of European Psychiatrists
|
April 12, 2013
The role of limbic and cortical regions in schizophrenia: focus on dopamine
G Marchese, L Pani
Molecular Psychiatry
|
March 29, 2002
The substituted benzamides and their clinical potential on dysthymia and on the negative symptoms of schizophrenia
L Pani, G L Gessa
International Journal of Clinical Pharmacology Research
|
January 1, 1997
Evolution of the dopaminergic system and its relationships with the psychopathology of pleasure
L Pani, G L Gessa
Molecular Psychiatry
|
February 16, 2000
The role of stress in the pathophysiology of the dopaminergic system
L Pani, A Porcella, G L Gessa
The European Journal of Neuroscience
|
September 29, 1998
Delta9-tetrahydrocannabinol increases sequence-specific AP-1 DNA-binding activity and Fos-related antigens in the rat brain
A Porcella, G L Gessa, L Pani
Brain Research. Molecular Brain Research
|
January 1, 1996
Correlation between increased AP-1NGF binding activity and induction of nerve growth factor transcription by multiple signal transduction pathways in C6-2B glioma cells
A M Colangelo, L Pani, I Mocchetti
Psychopharmacology
|
January 1, 1989
Differential postmortem release of noradrenaline and dopamine from rat brain
Z L Rossetti, L Pani, G L Gessa
Page
of 7